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COMMENTARY Open Access
Lost in the shadows: reflections on the dark
side of co-production
Oli Williams1,2*, Sophie Sarre1, Stan Constantina Papoulias3, Sarah Knowles4, Glenn Robert1, Peter Beresford5,
Diana Rose3, Sarah Carr6, Meerat Kaur7 and Victoria J. Palmer1,8
Abstract
This article is a response to Oliver et al.’s Commentary ‘The dark side of coproduction: do the costs outweigh the
benefits for health research?’ recently published in Health Research Policy and Systems (2019, 17:33). The original
commentary raises some important questions about how and when to co-produce health research, including
highlighting various professional costs to those involved. However, we identify four related limitations in their
inquiry, as follows: (1) the adoption of a problematically expansive definition of co-production that fails to
acknowledge key features that distinguish co-production from broader collaboration; (2) a strong focus on
technocratic rationales for co-producing research and a relative neglect of democratic rationales; (3) the
transposition of legitimate concerns relating to collaboration between researchers and practitioners onto work with
patients, service users and marginalised citizens; and (4) the presentation of bad practice as an inherent flaw, or
indeed ‘dark side’, of co-production without attending to the corrupting influence of contextual factors within
academic research that facilitate and even promote such malpractice. The Commentary’s limitations can be seen to
reflect the contemporary use of the term ‘co-production’ more broadly. We describe this phenomenon as
‘cobiquity’ – an apparent appetite for participatory research practice and increased emphasis on partnership
working, in combination with the related emergence of a plethora of ‘co’ words, promoting a conflation of
meanings and practices from different collaborative traditions. This phenomenon commonly leads to a
misappropriation of the term ‘co-production’. Our main motivation is to address this imprecision and the
detrimental impact it has on efforts to enable co-production with marginalised and disadvantaged groups. We
conclude that Oliver et al. stray too close to ‘the problem’ of ‘co-production’ seeing only the dark side rather than
what is casting the shadows. We warn against such a restricted view and argue for greater scrutiny of the structural
factors that largely explain academia’s failure to accommodate and promote the egalitarian and utilitarian potential
of co-produced research.
Keywords: Co-production, collaboration, participatory research, collaborative research, applied health research,
research impact, dark logic, unintended consequences, user involvement, patient and public involvement
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“Synergetic outcomes can be fostered to a much
greater extent than our academic barriers have let us
contemplate.” Elinor Ostrom ([1], p. 1083, emphasis
added)
‘Cobiquity’: what is lost when any form of
collaboration becomes ‘co-production’?
In a recent article, Oliver et al. [2] encourage consideration
of a number of important questions related to co-
production in research, in particular, under what circum-
stances should co-production be advocated rather than
other (e.g. consultative) approaches, and what types of in-
frastructure are needed to support productive coproduction?
These are important questions for researchers, organisa-
tions, citizens and funders to consider before promoting or
undertaking participatory research of any kind. As re-
searchers in this field, we welcome the authors’ call for
greater recognition of the skilled nature of such work, their
sympathetic discussion of the personal costs experienced by
some professionals involved, and their willingness to iden-
tify inequities in labour and reward. However, Oliver et al.
[2] pursue these useful lines of inquiry with a problematic-
ally expansive definition of co-production, which is simul-
taneously restricted by largely technocratic and
instrumental rationales for co-producing research. We
challenge these views by drawing on the foundational work
– and subsequent critiques – that underpin the concept of
co-production and its evolution since the early 1970s. Our
main concerns are how the limitations of Oliver et al.’s [2]
critique neglects the unique and vital perspectives of pa-
tients, service users and marginalised citizens, and how this
may have a detrimental impact on efforts to enable co-
production with marginalised and disadvantaged groups.
Additionally, we advocate for greater consideration of the
structural inequalities in academia and beyond that impede
co-production.
The context for the original article – and our response
– is a “participatory zeitgeist”, defined by a confluence of
social, cultural and political change leading to increasing
interest in methods for citizen engagement, public partici-
pation and involving people with relevant lived experience
in the tasks of health system (re)design and service im-
provement [3]. Oliver et al. [2] acknowledge this by stating
that there are “many forms of collaborative research prac-
tices” and a “multiplicity of modes by which researchers
may interact with stakeholders”. However, the broad use
of ‘stakeholders’ throughout their Commentary does not,
in our view, sufficiently distinguish between service users,
public contributors and professionals (e.g. healthcare prac-
titioners, commissioners, policy-makers and industry part-
ners). Such distinctions implicate very different types of
collaborative work, based on differences in expertise, ex-
perience and power, and we contest whether the latter
(partnerships exclusively between or primarily led by re-
searchers and professionals) should be referred to as co-
production.
Oliver et al.’s [2] working definition of co-production
as “the joint working of people who are not in the same
organisation to produce goods or services” originates from
the work of Ostrom [1]. The expansive nature of this
definition facilitates an interpretation that almost any
service or product development that occurs between
people who are not formal work colleagues is, by defin-
ition, co-produced. The utility of this definition was
questioned over a decade ago when it was argued that
“partnership is now so normal in services as to render
such definitions trivial” ([4], p. 847). Oliver et al. [2] are
certainly not alone in employing a broad definition of
co-production. British think tanks confused the matter
early in the twenty-first century by essentially creating a
“hybrid co-production discourse” by using the language
of radical power sharing to promote entrepreneurial
government [5]. Therefore, Oliver et al.’s [2] working
definition to some extent simply reflects the reality of
the term’s contemporary use by funders, policy-makers
and researchers. However, such usage represents a
phenomenon that we term ‘cobiquity’ – an apparent appe-
tite for participatory research practice and increased em-
phasis on partnership working, in combination with the
related emergence of a plethora of ‘co’ words, promoting a
conflation of meanings and practices from different col-
laborative traditions. This phenomenon commonly leads
to a misappropriation of the term ‘co-production’ as the
conflation disregards significant differences between col-
laborative traditions, such as who is involved, how they
are involved, the experiences people bring, and to what
extent such processes address structural and interpersonal
inequalities in power.
Notably, Ostrom went on to clarify that co-production
“implies that citizens can play an active role in produ-
cing public goods and services of consequence to them”
([1], p. 1073). However, while some passing references to
patient and public involvement are made, consideration
of the centrality of patients, service users and citizens to
the theory and praxis of co-production is almost entirely
absent in Oliver et al.’s [2] critique. Neglecting this fun-
damental aspect may account for the peer-reviewer’s
negative response to the initial draft, commenting that it
did “a disservice to those who are working hard to fully
engage in hearing the patient voice, and allowing that
voice a place at the research table” ([6], p. 2). This over-
sight could have been avoided if the Commentary more
fully appreciated the various rationales for co-producing
research. Instead, by defining co-production as partner-
ship working between people in different organisations,
Oliver et al. [2] muddy the waters – their critique in-
accurately transposes concerns that quite legitimately
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relate to inter-organisational collaboration between
researchers and practitioners onto work with patients,
service users and marginalised citizens. Addressing this
imprecision is one of our main motivations for writing
this response.
Oliver et al.’s [2] adoption of a working definition of co-
production, which essentially merely describes collabor-
ation, may explain why the National Institute for Health
Research’s Collaborations for Leadership in Applied Health
Research and Care (NIHR CLAHRCs) are their example of
a “truly coproductive” approach – especially given how
common it is for researchers to describe applied health re-
search in this way [7, 8]. This is particularly revealing when
paired with their assertion that often “a financial contribu-
tion by the stakeholder is indicative of an authentic copro-
duction partnership” ([2], p. 3). Few would regard the
CLAHRC network as a paragon of co-produced research,
although it is certainly recognised for having had a remit
for collaboration (considered novel when the network was
conceived in 2008) to address the long-standing transla-
tional gap between health(care) research and practice [9].
The surprising notion that a financial contribution from
the ‘stakeholder’ is required to confirm the authenticity of a
co-production partnership demonstrates that Oliver et al.
[2] have relatively powerful (e.g. industry) partners in mind.
This frames co-production as primarily a potential means
for researchers to work with practitioners to ensure re-
search addresses the central concerns of service providers
rather than, for instance, for affording patients, services
users and/or marginalised citizens more power to address
their needs and concerns. Again, Oliver et al. are not alone
in addressing co-production in research as primarily an en-
deavour for bringing together researchers and ‘practitioners’
[10]. Such an approach may increase the likelihood of ser-
vice providers implementing research findings and there-
fore be important in a ‘knowledge into action’ model [11].
However, it stands in rather stark contrast to the egalitarian
tradition more commonly aligned with co-production
through Ostrom’s seminal work [12–14], patient and com-
munity activism [15–19], and Cahn’s conceptualisation
[20], which more explicitly locates power and worth with
citizens in order to address issues of social justice.
While collaborative (as opposed to co-produced) re-
search may increase knowledge translation and uptake,
it does not necessarily share the aim of making the con-
ception or delivery of such research or services – or in-
deed the design process – more egalitarian, democratic
or transparent. The phenomenon of cobiquity leads to
these critical elements of co-production being neglected,
for example, consideration of the role of power and the
goal of enacting relationships that (unlike traditional re-
search collaborations) address the needs of patients, ser-
vice users and/or marginalised citizens, in part through
ascribing legitimacy to ‘lay’ knowledge [20–24]. This is
not to claim that Oliver et al. [2] are unaware of the ethical
and political underpinnings commonly considered essential
to the theory and praxis of co-production – these are briefly
acknowledged in their Commentary – but rather to empha-
sise that their adopted definition and technocratic priorities
allow for, and could even be considered to promote, ‘co-
produced’ research with marginal roles for service users,
patients and/or marginalised citizens or research without
them entirely. For instance, the focus on utilising co-
production to make research “implementation ready” leads
Oliver et al. to argue that “there may be alternative ways to
achieve this without risking the costs [of co-production]”
([2], p. 8) without acknowledging that alternatives are liable
to reduce the focus on inclusivity and equity (an outcome
we regard as a ‘cost’).
Bringing rationales for co-production to the fore
For clarity, we are not indulging in mere semantic quib-
bling or endeavouring to draw “clear lines along blurred
boundaries” as a form of “unhelpful guarding of territory”
([25], p. 1–2). Nor are we claiming that co-production
should be considered the ‘gold standard’ or only way to
approach participatory research – in any given situation,
multiple factors will influence which participatory method
is needed. Rather, we are attempting to highlight distinct-
ive ethical and political features of co-production. These
have tended to get diluted or lost altogether as the appli-
cation of the term has expanded.
Equally, we do not claim there is or needs to be a sin-
gle definition; not all co-production looks the same and
it can be variously transformative or additive in its intent
and effect [26]. While standardisation would belie this
complexity, lack of standardisation does not legitimise
labelling any or all forms of collaboration as ‘co-produc-
tion’. The trend for doing so, what we term ‘cobiquity’,
has led to co-production now being used to describe a
“fragmented set of activities, expectations and rationales”
([27], p. 427). Despite this, there are key features and,
particularly, values of co-production that are more gen-
erally considered common and essential. In making
these features explicit, it becomes apparent that consid-
ering numerous and varied forms of research collabor-
ation to be co-production risks losing sight of these
critical qualities. In particular, the deliberate egalitarian
rationale for co-production makes it stand out against
other forms of collaboration or co-working. It is this as-
pect which we think is missing from the arguments put
forth in the Oliver et al. Commentary [2].
Co-production, as understood in the expansive and di-
verse literature spanning from Ostrom [13] to Cahn [20]
to Hickey et al. [23], offers a process whereby profes-
sionals and those traditionally on the receiving end of
their ‘expertise’ (e.g. patients/service users/marginalised
citizens) can collaborate with the goal of achieving
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outcomes that arguably cannot be achieved otherwise. It
should engage the talents and experience of all involved
and support the egalitarian relations and conditions
needed to make the most of them. Logically, there is an
expectation that these principles should apply to co-
production in research (the focus of the Oliver et al.
Commentary [2]) and that this means to some extent “re-
searchers giving up power and control they have inherited
through its historical and structural distribution through-
out the system” ([28], p. 1275). Therefore, inherent to co-
producing research is bringing together patients/service
users/marginalised citizens with researchers and profes-
sionals/practitioners and attempting to form equitable
partnerships. This extends to patients/service users/mar-
ginalised citizens making meaningful contributions to
agenda-setting and the formation of research questions,
not merely being ‘involved’ once these important decisions
have been made by those who traditionally hold power in
research settings. This draws otherwise excluded perspec-
tives and understandings into strategic and procedural
decision-making processes. That is to say, there is a clear
egalitarian rationale supporting the co-production of re-
search. Any research process labelled ‘co-production’
should therefore be assessed against the efforts made, and
outcomes achieved, in alignment with these key features.
Oliver et al. [2] synthesise four main rationales for co-
production from the literature – substantive, instrumental,
normative and political. These can be subsumed within the
two overarching rationales for patient and public involve-
ment in health(care) outlined by Martin [29], namely
technocratic (substantive, instrumental) and democratic
(normative, political). This further refinement helps bring
into focus the prioritisation throughout Oliver et al.’s [2]
Commentary of the attainment of technocratic outcomes
that uphold established research convention and benefit re-
search careers, rather than the achievement of democratic
values that benefit service users/patients/marginalised citi-
zens. For example, they describe “widespread advocacy” for
co-production as “troubling” on the basis that “there is a
significant dearth of empirical evidence about coproduction
processes and outcomes” ([2], p. 6). While evaluation can be
useful, a democratic rationale does not require a sound
evidence-base to justify the normative desirability of co-
production. However, the Commentary gave short shrift to
arguments more aligned with democratic rationales [30] –
for example, addressing abuses of patient rights and related
long-standing and enduring inequalities in power and influ-
ence between health(care) providers/researchers and pa-
tients/service users/citizens [31, 32].
Having referred to co-production as an “exciting ap-
proach” for health research, the authors caution that it
“should be done for the right reasons and in the right
way”. This begs the question: who decides what is right?
We found very little in the Oliver et al. Commentary [2]
to suggest that deciding what is ‘right’ in this context
should be the task of anyone other than researchers or
indeed their funders/employers. This is demonstrative of
Oliver et al.’s [2] adoption of a technocratic approach to
value which prioritises the specific needs of researchers
and more broadly the perceived needs of research and
science. This technocratic prioritisation is not explicitly
stated in the Commentary but largely acts to define the
considerations and recommendations within it. For in-
stance, Oliver et al. [2] argue that co-production in re-
search is more suitable when “the policy or programme
is widely regarded as a ‘good thing’ and the findings un-
likely to be contested”, and less needed when “the nature
and purpose of the policy or programme is relatively well
defined and agreed upon” (as outlined in Table 2, p. 7).
In contrast, we argue that it is precisely these assump-
tions that should be laid open to challenge through pro-
cesses of co-production.
Costs of co-production or poor academic practice?
A full consideration of the tension and reciprocity be-
tween the technocratic and democratic rationales is be-
yond the scope of this paper. However, we outline this
well-established distinction to highlight how, by neglecting
democratic rationales for the co-production of research,
Oliver et al. [2] perceive what we would describe as bad
practice (i.e. ‘co-production’ that fails to adhere to the key
features of this egalitarian tradition) as inherent flaws, or
indeed the “dark side”, of co-production. The focus on
technocratic value may account for the descriptions of
‘costs’ as static features that can be measured and assessed
to determine whether co-production is ‘worth it’. The lim-
itations this oversight imposes on the Commentary are
evident in each of their core arguments about the “chal-
lenges and costs” of co-production (which we have
adopted as sub-headings and responded to in the discus-
sion below). By contrast, an egalitarian understanding asks
who experiences these costs and what the alternative value
could be of properly addressing them. Through this lens,
we argue that each of the proposed challenges and costs
can be understood as systemic or cultural barriers around
power in research, which not only vulnerable partners
(e.g. patients) but also researchers themselves can be detri-
mentally impacted by.
Practical costs
The basis for this argument is that co-produced research
“is expensive, as it requires the presence or time of multiple
actors who are often not on site, have other primary re-
sponsibilities, or need travel or other reimbursement” ([2],
p. 3). However, simply applying an economic logic would
suggest co-production is relatively inexpensive when com-
pared to international research collaborations and aca-
demic ‘networking’ activities. Likewise, in practice, the
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issue of ‘reimbursement’ is negligible in comparison to re-
search staff costs, especially as in many instances patients/
service users/citizens donate their time for free as their in-
volvement is – unfortunately still – rarely sufficiently bud-
geted for by researchers.
The insufficiency of funding is emphasised by Oliver
et al.’s adjoining observation that “this type of work is often
added on (to ‘real research’) with little thought for how to
properly resource it” ([2], p. 5). An economic critique of co-
production should ask why it is that co-production is so
rarely adequately considered or costed in research design.
Such inquiry might offer greater insight into why co-
production can be viewed as unequally burdening some
researchers. Our view is that the low priority accorded to
co-production in research is due to long-standing structural
inequalities in academia. These have led to a disproportion-
ate expectation/obligation on those who occupy less presti-
gious academic positions to carry out this type of work
with insufficient resources – as suggested by Oliver et al.
[2] and evidenced by a recent evaluation of community–
university partnerships [33]. This is not a legitimate justifi-
cation for dismissing co-production. Rather, it should lead
researchers to be critical of the structural inequalities play-
ing out in academia, which undermine both the importance
of more participatory research approaches and the status
and labour of those who undertake them.
Instead, Oliver et al. present a skill deficit in research
as a failing of co-production; they argue that co-
production requires interpersonal skills that “not all aca-
demics are trained in or endowed with” ([2], p. 5). Our
experience is that the interpersonal skills that facilitate
co-production do tend to be undervalued in research.
However, this merely highlights a need for these skills to
be better valued and developed in the research commu-
nity, not a cost of co-production.
Personal costs to researchers
The authors argue that “inherent power imbalances and
conflicts” in co-produced research play out as interpersonal
tensions, difficult conversations and/or outright disagree-
ment ([2], p. 5). While we may want to avoid unconstruct-
ive conflict, difficult conversations or disagreements can be
a welcome sign that different views, values, perspectives
and experiences are being considered and discussed as part
of a relational process. As Facer and Enright suggest, “If it
feels too easy, you probably aren’t doing it right” ([33], p.
57); this is not to dismiss the “emotional labour of working
collaboratively” ([2], p. 5) nor the challenges that will mean
co-production is not always an entirely positive experience
for all involved [34]. However, most research involves col-
laboration (albeit usually exclusively between researchers),
and emotional labour, while unacknowledged, is intrinsic-
ally bound to such work. We argue that established hier-
archies in academia and the relative power differences
within research teams carry greater potential for emotional
and career costs for researchers than co-production. Fur-
thermore, in focusing on conflict, stress and burnout, the
Commentary ignores the numerous examples where both
researchers and ‘stakeholders’ find the process immensely
rewarding (e.g. [35]). This is common in healthcare im-
provement research, where co-production provides the
tools and opportunities to improve services that themselves
cause stress and burnout. Again, it is important to acknow-
ledge the cumulative effect of the structural inequalities that
lead to the labour of co-production being unevenly distrib-
uted, i.e. overworked and often precariously employed ‘jun-
ior’ staff undertaking the challenge of co-production on top
of everything else. Academic hierarchies, competing de-
mands and precarity of employment exacerbate the poten-
tial for conflict, stress and burnout for such researchers;
these should not be presented as hazards of co-production
but rather as demonstrative of wider structural issues.
Professional costs to researchers
Central to this argument is that co-production obstructs
“seeking research funding, writing publications in impact-
ful journals, doing administration, and teaching” and
that this “is a huge ask for academics” ([2], p. 5). We en-
courage a more structural analysis that questions what
has come to be seen as valuable within academia – why,
for example, is publishing in high impact journals valued
more highly than working directly with fellow citizens to
improve society? Admittedly, achieving this within
current institutional structures presents significant chal-
lenges but these are not conflicting values. If – as Oliver
et al. [2] suggest – researchers who co-produce are
regarded as “light-weight” within academia, and co-
produced outputs considered “lower quality” and “simply
hard to publish”, then we must challenge those assump-
tions and constraints. Indeed, why would researchers seek
to maintain the status quo given widespread anxiety and
discontent relating to the ever-increasing performance
management and metricising of their contributions? Add-
itionally, the notion that successful co-production requires
researchers to “engage with no expectation of a guaranteed
impact as measured in academia” ([2], p. 5) undoubtedly
makes co-production extremely challenging but only if we
accept that a narrowly defined output-focused culture is
what academics should embrace.
Costs to research
The authors point to delays caused by the additional work
of recruiting and engaging with stakeholders. However,
these activities only cause delays if research timetables do
not reflect a thoroughly considered co-production ap-
proach. And of course, in this regard, recruitment to trials
is hardly unproblematic [36]. The authors also fear that ten-
sions later in the research process arising from differences
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in opinion on how to interpret findings and frame recom-
mendations “may result in research being co-opted or re-
searchers being silenced” ([2], p. 5). This is an example of
where their argument might quite legitimately relate to
inter-organisational collaboration but less so to co-
production with patients/service users/marginalised citi-
zens. In the latter context, claiming it is researchers who
are in danger of being silenced seems naive given that one
of the most pervasive critiques of participatory practice in
healthcare/health research is that it commonly fails to rep-
resent and legitimise the voices and perspectives of service
users and people from marginalised groups [22, 37–40].
Academics often have an implicit epistemology that privi-
leges a certain hierarchy of knowledge and evidence (in re-
search). Patients, service users and/or marginalised citizens
who cannot speak the language of research are thereby si-
lenced and their experiential, collective knowledge devalued
and often excluded entirely [41–44]. This is a form of epi-
stemic injustice [45]. In other words, when co-production
fails to address pre-existing power dynamics in research it
is service users and lay partners – not researchers – who
are most likely silenced.
Additionally, such norms suggest researchers are
uniquely qualified to determine research priorities with-
out fully recognising that the translational gap between
research and practice was/is largely due to researchers
failing to conduct research with, and of relevance to,
healthcare providers, policy-makers, patients and the
public [46, 47]. Oliver et al. [2] argue that co-production
can lead to “dull” and “derivative” research that is poten-
tially damaging to academic careers. While it may not be
their intention, their ambiguous framing of stakeholders
leaves these statements open to the interpretation that
they relate to the needs and preferences of service users, pa-
tients and marginalised citizens. This is a prime example of
why transposing concerns regarding inter-organisational
collaboration onto work with patients/service users/margin-
alised citizens is ill-advised. However, it also reflects the
need for researchers and funders to show more interest in
the everyday realities of people’s lives, rather than pushing
them further to the margins of academic endeavour.
Costs to stakeholders
Oliver et al. ([2], p.6) express concern for the vulnerabil-
ity of stakeholders – “especially policy-makers” – who
share sensitive information. However, looking outside
the policy field, quality improvement research (and
much else besides) is grounded in the identification of
uncertainties [48], inefficiencies [49] and mistakes [50].
If we want research to enable improvement at broader
institutional levels, then it is surely our role as re-
searchers to surface such issues through ethical practices
that protect our partners. Where is the value in defend-
ing a status quo where people cannot admit to feeling
uncertain or making mistakes? Why not see creating safe
spaces for professionals, patients, service users and citi-
zens alike to experience and share vulnerability as some-
thing worth celebrating and promoting?
Batalden writes of the central role of sharing vulnerabil-
ity in the building of trust and respect between patients
and professionals through co-production; he argues
“[b]oth parties bring their knowledge, skill, and habits to
the service making task. A willingness to be vulnerable
arises from being fully present and able to fully engage an-
other person.” He explains that, while this “idealised model
does not always exist in practice” it grants “professionals
important permission to be vulnerable and to value more
fully the knowledge and skills patients bring to making
health services” ([51], p. 2). It seems illogical that Oliver
et al. [2] perceive researchers to lack interpersonal skills
and yet consider co-production problematic precisely be-
cause it puts professionals in positions that – in safe and
supportive contexts – facilitate interpersonal develop-
ment. In contrast, we argue for a need to create and evalu-
ate contexts and supporting infrastructure to facilitate the
building of trust and respect between researchers, profes-
sionals, patients, services users and citizens. The relative
nature of vulnerability needs to be accounted for in the
development of such environments as often the stakes are
higher for those without professional prestige.
Costs to the research profession
The closing argument is that working closely with parties
with clearly vested interests risks transforming researchers
into “simply one more lobby group” ([2], p. 6) as it has the
potential to reduce trust in scientists and science. Often,
such arguments come from those adopting a strict positivist
position, which assumes the neutrality of researchers and
views those with vested interests as invaliding the scientific
endeavour. The claim implies that researchers’ own values
and interests in participating in a research study are intrin-
sically of a different (moral?) order to those of other part-
ners. We argue that research would benefit from reflection
on all participants’ vested interests (including researchers’)
and their influence on data collection and analysis. Add-
itionally, the “one more lobby group” reference is a further
example of where the authors transpose legitimate con-
cerns about partnerships between researchers and practi-
tioners to co-production between researchers and patients/
service users/marginalised citizens. This transposition
equates the egalitarian objectives of co-production – to cre-
ate inclusive research practice capable of addressing the
needs of patients/service users/marginalised citizens and
society more broadly – with concerns as to the potentially
corrupting role of, for example, industrial or political vested
interests.
Overall, the thrust of this argument is that co-
production promotes poor research practice and thereby
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undermines research. Our counterargument is that the
tradition of co-production does not inherently promote
poor practice; much the opposite – it gives greater con-
sideration than is usual within academic research to is-
sues such as representation, diversity, participation and
dissemination. Conversely, there are many academic
norms that lead to poor practice and should promote a
mistrust in scientists and science, for example, the struc-
tural inequalities and organisational norms that result in
the gendering of research hierarchies, disciplines, topics,
participation and findings [52–54]. Wider adoption of
the co-production tradition has the potential to help
academia overcome the structural issues of exclusion,
which pose a far greater threat to the credibility of
science.
What constitutes the dark side of co-production?
Contemplating the research context
In acknowledging that Oliver et al. [2] have raised im-
portant questions in relation to co-production and
agreeing with some of their broader points relating to
partnership working, we hope this response is received
in the spirit intended – to further the debate and dia-
logue around this important but contentious area. Here,
we are responding to the imprecision of their definition
of co-production, its neglect of the egalitarian impera-
tive, and how this appears to have led them to select the
wrong targets. Our argument is that this serves to make
a scapegoat (co-production) for wider systematic failure
(hierarchical and market-driven research environments).
This blunts what may have otherwise been useful
critique.
To clarify, we are not arguing for uncritical adoption
of co-production – much the opposite. Even advocates
of co-production acknowledge it is not always the most
appropriate approach. Indeed, Ostrom herself clarified
“coproduction is not, of course, universally advantageous”
([1], p. 1082). However, critique must come from a
broader perspective than the one adopted by Oliver
et al. [2]. It should take into consideration (1) the egali-
tarian rationale for co-production to further the rights
and needs of patients, service users and marginalised cit-
izens, (2) the wider structural issues of academia that
impinge upon co-production in research, and (3) over
40 years of politically engaged research in this area. We
are all involved in such research [3, 15, 28, 44, 55–62]
and to that end, conducting work that Oliver et al. [2]
appear to assume is currently absent.
We agree that doing co-production “recklessly” or “dis-
courteously” has significant costs and that “mindful en-
gagement is essential for the ethical practice of research”
([2], p. 6, 8). However, it is illegitimate to separate bad
practice from the contextual factors facilitating and even
promoting it, especially if such malpractice is then
presented as the dark side of a process that has been
misrepresented. The phenomenon of ‘cobiquity’ has di-
luted the legitimacy of both co-production and subse-
quent critiques of it, clouding inquiry and misdirecting
what could otherwise be useful and therefore welcome
scrutiny. Oliver et al. provide evidence of this when pre-
senting examples of malpractice that are not inherent to
the practice of co-production, nor in keeping with its
egalitarian tradition. This is neither new nor helpful;
we have already encountered researchers in the field
using the Commentary as a rationale for not includ-
ing patients, service users and the public in research
design.
While one of us has argued elsewhere that co-
production in the mental health field is currently an im-
possibility because of the very varied and entrenched
power dynamics involved, especially for racialised groups
[44], in contrast to Oliver et al. [2], this argument was
not a call to minimise or avoid co-production. Rather, it
was a call to attend to these issues so that real structural
and social change might happen. Or – if this cannot
happen – to increase scrutiny of practice labelled ‘co-
production’ to highlight the limitations of practice that
is largely disconnected from the egalitarian imperative.
The Oliver et al. Commentary [2] merely highlights the
value of ‘dark logic modelling’ more broadly – develop-
ing models to anticipate the most plausible unintended
harmful impacts and associated mechanisms of health
interventions and the need to guard against them from
the outset of projects [63]. Quite simply, doing anything
badly can be a costly risk.
Here, it is important to note that Oliver et al.’s Com-
mentary [2] is by no means original in addressing the ‘dark
side’ of co-production. Others writing of the ‘dark side’ of
co-production – yet not cited in Oliver et al.'s Commentary
– have described “co-contamination” [64] (an extension of
the concept of “co-destruction” [65], which was presented
as a logical counter to co-creation) and the “seven evils” of
co-production [66], as well as emphasising the contextual
distinction of “co-production under the financial crisis”
[67]. For example, Steen et al. [66] raise the worrying
trend of co-production projects being inequitable in de-
sign and appeal and consequently involving only already
privileged population groups and by extension further
marginalising others. Given the legitimacy of existing dark
side critiques and our holding Oliver et al. in high regard
for having written elsewhere of the potential for health in-
terventions to have “equity harms” [68] and for suggest-
ing radical shifts in health promotion for the
furtherance of health equity [69], we were surprised
that equity issues (beyond those concerning the division
of collaborative research labour between researchers)
were not more prominent in their delineation of co-
production’s dark side.
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Existing dark side critiques recognise that the context
in which co-production occurs largely determines the
nature of the process and outcomes. For instance, when
Williams et al. assess what they term “public value fail-
ure” resulting from co-production (i.e. the dark side of
co-production) they make it clear that the “emphasis is
not necessarily on highlighting the failure of co-
production, but rather to shed light upon key factors that
impede effective co-production processes” ([64], p. 703).
Steen et al. [66] even go so far as to explain one of the
seven evils of co-production as how it can reinforce
structural inequalities when used as a means of austerity
to help governments abdicate their responsibilities to the
public. For this reason, Fotaki warns against co-
production “instigating a race to the bottom” ([67], p.
463). Similarly Moini argued that a certain “technicaliza-
tion of participation” ([70], p. 158) works to shore up
neoliberal regimes by creating the appearance of consen-
sus and shared responsibility between different social ac-
tors and by offering technical solutions to what are
essentially political problems (see also [19, 43]). Oliver
et al. [2], however, do not offer a comparable critique.
Instead, the arguments presented appear unaware of, or
unconcerned by, how research predominantly provides a
context for which co-production is ill-fitted. This is not,
as suggested, because the practice of co-production is in-
herently flawed but rather because the current context
and norms of research (or what they term “business-as-
usual rules” ([2], p. 5) are corrupting. Their critique
makes little reference to the relational spaces in research
within which co-production occurs and overlooks essen-
tial dimensions of power. Where relationships have been
mentioned, the reference is to researchers “calling on fa-
vours and being able to provide favours in return” and
managing “sometimes tense relationships” ([2], p. 5) but
the analysis does not explicitly address the power rela-
tions playing out in these instances. Doing so would
highlight how the reality of inequitable power dynamics
and deep-seated epistemological assumptions make co-
production a highly political practice that must endeav-
our to transform traditional research processes as much
as it does produce implementable outcomes. Oliver et al.
[2] stray too close to ‘the problem’ of ‘co-production’
seeing only the dark side rather than what is casting the
shadows.
Conclusions: addressing ‘academic barriers’ to co-
production and moving beyond technocratic
priorities
We started our Commentary with Ostrom’s [1] quotation
regarding ‘academic barriers’ preventing researchers from
seeing greater potential in what can be achieved through
co-production. We believe Oliver et al.’s Commentary to be
an illustration of this; they argue co-production carries
“significant risks for academics” because it requires them to
“adopt practices far from those traditionally taught,
adopted, recognised or rewarded by the academy” ([2], p. 3).
This highlights that their primary concern with regards to
the ‘costs’ of co-production is the need for researchers to
protect their own interests (and careers) in what is an ex-
clusionary system. Crucially, this is a status quo that is in-
creasingly driven not by what they might construe as
traditional values, but rather the principles of New Public
Management, i.e. technocratic priorities, bureaucratisation
and market fundamentalism [71, 72]. This concern in turn
casts co-production as a corrupting force threatening the
legitimacy of scientific endeavour and academic ‘achieve-
ment’. Their secondary concern appears to be how co-
production can be shaped and used to help researchers play
this competitive game better, thus allowing exclusionary
academic convention driven by grant revenue generation
and the need to create ‘impact case studies’ and inter-
nationally significant publications to fulfil national stan-
dards of ‘research excellence’ to continue unchanged. This
misconstrues what we would characterise as the moral
virtue of research and researchers as well as revealing how
a “culture of hit-and-run research” ([2], p. 6) – driven by
metrics and funder priorities that can often be disconnected
from public value and egalitarian imperatives – perpetuates
an instrumentalism that is unhelpful both to those outside
such academic endeavours and, increasingly, to academics
themselves.
Our main conclusion is that, in not addressing the struc-
tural factors that largely explain academia’s failure to ac-
commodate and promote the egalitarian and utilitarian
potential of co-produced research and instead focusing al-
most exclusively on technocratic utility, Oliver et al.’s Com-
mentary [2] serves to reinforce the foundations of the
status quo. Interestingly, Oliver et al. argue “political rea-
sons for engaging in coproductive research may be the least-
discussed, yet most important rationale made by re-
searchers” ([2], p. 8). This appears to illuminate a blind spot
in the authors’ argument. Far from being “the least dis-
cussed”, the emancipatory politics of co-production are ex-
plicitly and consistently articulated by those who advocate
this practice and we contribute this Commentary to that lit-
erature [19–21, 30, 73–75]. Additionally, it seems inconsist-
ent for Oliver et al. [2] to make this statement without also
explicitly discussing their own rationale. We argue it is
overly technocratic and, consequently, while the Commen-
tary is presented as apolitical, it leaves unacknowledged the
significant opportunity costs and harms attributable to re-
searchers neglecting egalitarian rationales. The significance
of this is that their Commentary serves to make health re-
search less inclusive and further removed from the public it
should be serving. Therefore, Oliver et al. [2] provide a use-
ful reminder that, when adopting dark logic, it is important
not to get lost in the shadows.
Williams et al. Health Research Policy and Systems           (2020) 18:43 Page 8 of 10
Abbreviation
NIHR CLAHRCs: National Institute for Health Research Collaborations for
Leadership in Applied Health Research and Care
Acknowledgements
We are grateful to Alan Cribb (King’s College London) for usefully
commenting on an early draft of this paper.
Authors’ contributions
OW, SS and GR wrote the initial draft of this paper. CP, SK, PB, DR, SC, MK
and VP later made substantial intellectual and editorial contributions in an
ongoing interactive review cycle. All authors approved the submitted version
before submission.
Funding
OW is supported by the Health Foundation’s grant to the University of
Cambridge for The Healthcare Improvement Studies Institute.
OW, SS and GR are affiliated to the Samskapa research programme on co-
production led by Jönköping University. This is funded by Forte, the Swedish
Research Council for Health, Working Life and Welfare under grant agree-
ment no. 2018–01431. SS and GR receive funding from this grant.
SP is supported by the National Institute for Health Research (NIHR) Applied
Research Collaboration (ARC) South London at King’s College Hospital NHS
Foundation Trust. The views expressed are those of the author and not
necessarily those of the NHS, the NIHR or the Department of Health and
Social Care. During the preparation of the paper, SK was funded by an NIHR
Knowledge Mobilisation Research Fellowship.
DR is in receipt of Wellcome Investigator Award IA 203237/Z/16/ examining
knowledge generation and practice innovation by mental health service
users, survivors and people with psychosocial disabilities globally. She also
receives support from the NIHR-funded ARC South London. Neither funders,
nor the Department of Health and Social Care are responsible for the views
expressed here.
SC is in receipt of NIHR School for Social Care Research funding for a user-
controlled study on avoidable harm in mental health social care. The views
expressed in this paper are those of the author and not the NIHR SSCR, NHS,
the National Institute for Health Research or the Department of Health and
Social Care. MK is supported by the National Institute for Health Research
(NIHR) Applied Research Collaboration (ARC) Northwest London. The views
expressed are those of the author and not necessarily those of the NHS, the
NIHR or the Department of Health and Social Care.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King’s
College London, 4th Floor, James Clerk Maxwell Building, 57 Waterloo Road,
London SE1 8WA, United Kingdom. 2THIS Institute, Cambridge, United
Kingdom. 3Service User Research Enterprise, King’s College London, London,
United Kingdom. 4University of York, York, United Kingdom. 5University of
Essex, Colchester, United Kingdom. 6University of Birmingham, Birmingham,
United Kingdom. 7NIHR ARC Northwest London, London, United Kingdom.
8The University of Melbourne, Melbourne, Australia.
Received: 3 September 2019 Accepted: 2 April 2020
References
1. Ostrom E. Crossing the great divide: coproduction, synergy, and
development. World Dev. 1996;24(6):1073–87.
2. Oliver K, Kothari A, Mays N. The dark side of coproduction: do the costs
outweigh the benefits for health research? Health Res Policy Syst. 2019;17:33.
3. Palmer VJ, Weavell W, Callander R, Piper D, Richard L, Maher L, et al. The
Participatory Zeitgeist: an explanatory theoretical model of change in an era
of coproduction and codesign in healthcare improvement. Med Humanities.
2019;45(3):247–57.
4. Bovaird T. Beyond engagement and participation: User and community
coproduction of public services. Public Adm Rev. 2007;67(5):846–60.
5. Carr S. Who owns co-production? In: Beresford P, Carr S, editors. Social
Policy First Hand: An International Introduction to Participatory Welfare.
Bristol: Policy Press; 2018. p. 74–83.
6. Black A. The dark side of coproduction: do the costs outweigh the benefits
for health research? Open Reviewer’s Report. Health Research Policy and
Systems. 2019. https://health-policy-systems.biomedcentral.com/articles/1
0.1186/s12961-019-0432-3/open-peer-review.
7. Clarke J, Waring J, Timmons S. The challenge of inclusive coproduction: the
importance of situated rituals and emotional inclusivity in the coproduction
of health research projects. Soc Policy Admin. 2019;53(2):233–48.
8. Hewison A, Gale N, Shapiro J. Co-production in research: some reflections
on the experience of engaging practitioners in health research. Public
Money Manage. 2012;32(4):297–302.
9. Martin GP, McNicol S, Chew S. Towards a new paradigm in health research
and practice? Collaborations for Leadership in Applied Health Research and
Care. J Health Organ Manage. 2013;27(2):193–208.
10. Martin S. Co-production of social research: strategies for engaged
scholarship. Public Money Manage. 2010;30(4):211–8.
11. Graham ID, Tetroe J, Pearson A. Turning Knowledge into Action: Practical
Guidance on How to Do Integrated Knowledge Translation Research.
Adelaide: Lippincott Williams & Wilkins; 2014.
12. Ostrom E. Governing the Commons: The Evolution of Institutions for
Collective Action. Cambridge: Cambridge University Press; 1990.
13. Ostrom E, Parks RB, Whitaker GP, Percy SL. The public service production
process: a framework for analyzing police services. Policy Stud J. 1978;7:381.
14. Wall D. Elinor Ostrom's Rules for Radicals. London: Pluto Press; 2018.
15. Beresford P. Public participation in health and social care: exploring the co-
production of knowledge. Front Sociol. 2019;3:41. https://doi.org/10.3389/
fsoc.2018.00041.
16. Charlton JI. Nothing About Us Without Us: Disability Oppression and
Empowerment. Berkley: University of California Press; 2000.
17. Rabeharisoa V, Moreira T, Akrich M. Evidence-based activism: patients’, users’
and activists’ groups in knowledge society. BioSocieties. 2014;9:111–28.
18. Whitaker GP. Coproduction: citizen participation in service delivery. Public
Adm Rev. 1980;40:240–6.
19. Beresford P, Carr S, editors. Social Policy First Hand: An International
Introduction to Participatory Welfare. Bristol: Policy Press; 2018.
20. Cahn ES. No More Throw-Away People: The Co-Production Imperative.
Washington, DC: Essential Books; 2000.
21. Farr M. Power dynamics and collaborative mechanisms in co-production
and co-design processes. Crit Soc Policy. 2018;38(4):623–44.
22. Green G. Power to the people: to what extent has public involvement in
applied health research achieved this? Res Involv Engagement. 2016;2(1):28.
23. Hickey G, Richards T, Sheehy J. Co-production from proposal to paper.
Nature. 2018; https://www.nature.com/articles/d41586-018-06861-9.
Accessed 1 Mar 2020.
24. Pols J. Knowing patients: turning patient knowledge into science. Sci
Technol Hum Values. 2014;39(1):73–97.
25. Locock L, Boaz A. Drawing straight lines along blurred boundaries:
Qualitative research, patient and public involvement in medical research,
coproduction and co-design. Evid Policy. 2019. https://doi.org/10.1332/
174426419X15552999451313.
26. Glynos J, Speed E. Varieties of co-production in public services: time banks
in a UK health policy context. Crit Policy Stud. 2012;6(4):402–33.
27. Ewert B, Evers A. An ambiguous concept: on the meanings of co-
production for health care users and user organizations? Volunt Int J Volunt
Nonprofit Org. 2014;25(2):425–42.
28. Lambert N, Carr S. ‘Outside the Original Remit’: Co-production in UK mental
health research, lessons from the field. Int J Ment Health Nurs. 2018;27(4):
1273–81.
29. Martin GP. ‘Ordinary people only’: knowledge, representativeness, and the
publics of public participation in healthcare. Soc Health Illness. 2008;30(1):
35–54.
Williams et al. Health Research Policy and Systems           (2020) 18:43 Page 9 of 10
30. Verschuere B, Vanleene D, Steen T, Brandsen T. Democratic Co-Production:
Concepts and Determinants. Co-Production and Co-Creation. Abingdon:
Routledge; 2018. p. 243–51.
31. Faulkner A. Institutional conflict: the state of play in adult acute psychiatric
wards. J Adult Protect. 2005;7(4):6–12.
32. Rose D, Perry E, Rae S, Good N. Service user perspectives on coercion and
restraint in mental health. BJPsych Int. 2017;14(3):59–61.
33. Facer K, Enright B. Creating Living Knowledge: The Connected Communities
Programme, Community-University Partnerships and the Participatory Turn
in the Production Of Knowledge. Bristol: Arts and Humanities Research
Council; 2016.
34. Kara H. Identity and power in co-produced activist research. Qual Res. 2017;
17(3):289–301.
35. Scottish Co-production Network. 100 Stories of Co-production. 2019. http://
www.coproductionscotland.org.uk/learning/section/100-stories/. Accessed
12 Dec 2019.
36. Bower P, Wilson S, Mathers N. How often do UK primary care trials face
recruitment delays? Fam Pract. 2007;24(6):601–3.
37. Martin GP, Carter P, Dent M. Major health service transformation and the
public voice: conflict, challenge or complicity? J Health Serv Res Policy.
2018;23(1):28–35.
38. Ocloo J, Matthews R. From tokenism to empowerment: progressing patient
and public involvement in healthcare improvement. BMJ Qual Saf. 2016;
25(8):626–32.
39. Olesen BR, Nordentoft HM. Walking the talk? A micro-sociological approach
to the co-production of knowledge and power in action research. Int J
Action Res. 2013;9(1):67–94.
40. Mahmud S. Spaces for participation in health systems in rural Bangladesh:
The experience of stakeholder community groups. In: Cornwall A, Coelho
VSP, editors. Spaces for Change?: The Politics of Citizen Participation in New
Democratic Arenas. London: Zed; 2007. p. 55–75.
41. Dabashi H. Can non-Europeans think? London: Zed Books Ltd; 2015.
42. Green G, Johns T. Exploring the relationship (and power dynamic)
between researchers and public partners working together in applied
health research teams. Front Sociol. 2019;4:20. https://doi.org/10.3389/
fsoc.2019.00020.
43. Madden M, Speed E. Beware zombies and unicorns: toward critical patient
and public involvement in health research in a neoliberal context. Front
Sociol. 2017;2:7. https://doi.org/10.3389/fsoc.2017.00007.
44. Rose D, Kalathil J. Power, privilege and knowledge: the untenable promise
of co-production in mental “health”. Front Sociol. 2019;4:57. https://doi.org/
10.3389/fsoc.2019.00057.
45. Fricker M. Epistemic Injustice: Power and the Ethics of Knowing. Oxford:
Oxford University Press; 2007.
46. Robotham D, Wykes T, Rose D, Doughty L, Strange S, Neale J, et al. Service
User and Carer Priorities in a Biomedical Research Centre for Mental Health.
Abingdon-on-Thames: Taylor & Francis; 2016.
47. Cooksey D. A Review of UK Health Research Funding. London: The
Stationery Office; 2006.
48. Maben J, Taylor C, Dawson J, Leamy M, McCarthy I, Reynolds E, et al. A
realist informed mixed-methods evaluation of Schwartz Center Rounds® In
England. Health Serv Deliv Res. 2018;6(37):1–260.
49. Sarre S, Maben J, Griffiths P, Chable R, Robert G. The 10-year impact of a
ward-level quality improvement intervention in acute hospitals: a multiple
methods study. Southampton: NIHR Journals Library; 2019.
50. Jones A, Kelly D. Whistle-blowing and workplace culture in older peoples'
care: qualitative insights from the healthcare and social care workforce.
Sociol Health Illness. 2014;36(7):986–1002.
51. Batalden P. Getting more health from healthcare: quality improvement
must acknowledge patient coproduction—an essay by Paul Batalden. BMJ.
2018;362:k3617.
52. Perez CC. Invisible Women: Exposing Data Bias in a World Designed for
Men. New York: Random House; 2019.
53. Sugimoto CR, Ahn Y-Y, Smith E, Macaluso B, Larivière V. Factors affecting
sex-related reporting in medical research: a cross-disciplinary bibliometric
analysis. Lancet. 2019;393(10171):550–9.
54. Welch V, Doull M, Yoganathan M, Jull J, Boscoe M, Coen S, et al. Reporting
of sex and gender in randomized controlled trials in Canada: a cross-
sectional methods study. Res Integr Peer Rev. 2017;2(1):15.
55. Beresford P. Involving people, co-production and advocacy. In: Walden D,
editor. Reimagining Adult Social Care: Evidence Informed Practice, Evidence
Review. Totnes: Dartington Hall Trust; 2015.
56. Carr S, Patel M. Practical Guide: Progressing Transformative Co-Production in
Mental Health. Bath: National Development Team for Inclusion; 2016.
57. Kislov R, Wilson P, Knowles S, Boaden R. 5 The art of compromise: co-
production of evidence in applied health research. BMJ Evid Based Med.
2018;23(Suppl_1):A3.
58. Kjellström S, Areskoug-Josefsson K, Andersson Gäre B, Andersson A-C,
Ockander M, Käll J, et al. Exploring, measuring and enhancing the
coproduction of health and well-being at the national, regional and local
levels through comparative case studies in Sweden and England: the
‘Samskapa’ research programme protocol. BMJ Open. 2019;9(7):e029723.
59. Matthews R, Papoulias SC. Towards co-productive learning? The Exchange
Network as experimental space. Front Sociol. 2019;4:36. https://doi.org/10.
3389/fsoc.2019.00036.
60. Needham C, Carr S. Co-production: an emerging evidence base for adult social
care transformation. Social Care Institute for Excellence; 2009. https://lx.iriss.org.
uk/sites/default/files/resources/Co-production.pdf. Accessed 1 Apr 2020.
61. Papoulias C. Showing the unsayable: Participatory visual approaches and
the constitution of ‘Patient Experience’ in healthcare quality improvement.
Health Care Anal. 2018;26(2):171–88.
62. Williams O, Robert G, Martin GP, Hanna E, O’Hara J. Is co-production just
really good PPI? Making sense of patient and public involvement and co-
production networks. In: Bevir M, Waring J, editors. Decentering healthcare
networks. London: Palgrave; 2020.
63. Bonell C, Jamal F, Melendez-Torres G, Cummins S. ‘Dark logic’: theorising the
harmful consequences of public health interventions. J Epidemiol
Community Health. 2015;69(1):95–8.
64. Williams BN, Kang S-C, Johnson J. (Co)-contamination as the dark side of
co-production: public value failures in co-production processes. Public
Manag Rev. 2016;18(5):692–717.
65. Plé L, Chumpitaz CR. Not always co-creation: introducing interactional co-
destruction of value in service-dominant logic. J Serv Mark. 2010;24(6):430–7.
66. Steen T, Brandsen T, Verschuere B. The Dark Side of Co-Creation and Co-
Production: Seven Evils. Co-Production and Co-Creation. Abingdon:
Routledge; 2018. p. 284–93.
67. Fotaki M. Co-production under the financial crisis and austerity: a means of
democratizing public services or a race to the bottom? J Manag Inq. 2015;
24(4):433–8.
68. Lorenc T, Oliver K. Adverse effects of public health interventions: a
conceptual framework. J Epidemiol Community Health. 2014;68(3):288–90.
69. Gore D, Kothari A. Social determinants of health in Canada: are healthy living
initiatives there yet? A policy analysis. Int J Equity Health. 2012;11(1):41.
70. Moini G. How participation has become a hegemonic discursive resource:
towards an interpretivist research agenda. Crit Policy Stud. 2011;5(2):149–68.
71. Lorenz C. If you're so smart, why are you under surveillance? Universities,
neoliberalism, and new public management. Crit Inq. 2012;38(3):599–629.
72. Shore C. Audit culture and illiberal governance: Universities and the politics
of accountability. Anthropol Theory. 2008;8(3):278–98.
73. Pestoff V, Brandsen T, Verschuere B. New Public Governance, the Third
Sector, and Co-Production. Abingdon: Routledge; 2013.
74. Rose D. Participatory research: real or imagined. Soc Psychiatry Psychiatr
Epidemiol. 2018;53(8):765–71.
75. Voronka J. The Politics of 'people with lived experience'. Experiential
authority and the risks of strategic essentialism. Philos Psychiatry Psychol.
2016;23(3):189–201.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Williams et al. Health Research Policy and Systems           (2020) 18:43 Page 10 of 10
